Why is Cross Reactivity Important in Cancer Immunotherapy?
In cancer immunotherapy, cross reactivity can lead to unintended targeting of normal tissues that share similar antigens with cancer cells. This can result in off-target effects and autoimmune responses, complicating the treatment process and potentially causing harmful side effects. Understanding and managing cross reactivity is therefore critical to improving the safety and efficacy of immunotherapeutic strategies.